4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs

OBJECTIVES/GOALS: This study aims to assess the outcomes of a new virtual multidisciplinary immune-related toxicity (IR-tox) team implemented at Johns Hopkins Hospital. In particular, to understand if the IR-tox team’s input reduced the number of inpatient hospitalizations for irAEs for referred pat...

Full description

Bibliographic Details
Main Authors:	Aanika Balaji, Jiajia Zhang, Jarushka Naidoo
Format:	Article
Language:	English
Published:	Cambridge University Press 2020-06-01
Series:	Journal of Clinical and Translational Science
Online Access:	https://www.cambridge.org/core/product/identifier/S2059866120002393/type/journal_article

Similar Items

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
by: Alexander Batista-Duharte, et al.
Published: (2023-05-01)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
by: Laura C Cappelli, et al.
Published: (2023-03-01)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
by: Virginia Robles-Alonso, et al.
Published: (2022-06-01)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
by: Yi-Shan Teng, et al.
Published: (2023-07-01)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
by: Wanhai Ke, et al.
Published: (2020-04-01)

Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment
by: Saeed Moradian, et al.
Published: (2023-06-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

A case of readministration of nivolumab by treating with apremilast for psoriasiform eruption as irAE
by: Naohisa Ichiki, et al.
Published: (2021-06-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-05-01)

1245 Th17 and Type 2 CD8+ cytokine signatures predict irAEs in solid tumors
by: Evan J Lipson, et al.
Published: (2023-11-01)

A case of malignant melanoma with shrinking metastases after sequential severe irAEs
by: Aya Maekawa, et al.
Published: (2020-04-01)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
by: A Daban, et al.
Published: (2023-12-01)

Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
by: Elisa Giommoni, et al.
Published: (2021-08-01)

445 The relationship between immune-related adverse events (irAEs) and ctDNA status: exploratory analysis from IMvigor010
by: Thomas Powles, et al.
Published: (2023-11-01)

444 Unveiling immune-related adverse events (irAEs) and symptom burden in melanoma patients on adjuvant immune checkpoint inhibitors (ICIs)
by: Susan Peterson, et al.
Published: (2023-11-01)

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
by: Laura C Cappelli, et al.
Published: (2024-04-01)

Construction of a prognostic model for HCC based on ferroptosis-related lncRNAs expression and its potential to predict the response and irAEs of immunotherapy
by: Liangbo Dong, et al.
Published: (2023-03-01)

1237 Long term outcomes of severe endocrine immune-related adverse events (irAEs): adrenal insufficiency (AI) and insulin-dependent diabetes (IDDM)
by: Andrea Knezevic, et al.
Published: (2023-11-01)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
by: F Stephen Hodi, et al.
Published: (2021-05-01)

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
by: Brian W. Labadie, et al.
Published: (2019-11-01)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
by: Qi Ai, et al.
Published: (2022-06-01)

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
by: Dongyu Zhang, et al.
Published: (2021-12-01)

471 Pharmacokinetics of first and repeated dosing of non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392 in advanced cancer patients
by: Mei Tang, et al.
Published: (2021-11-01)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
by: Huanyu Zhou, et al.
Published: (2022-03-01)

Models for The IRAS Low Resolution Spectra of OH/IR Stars
by: Sung-Min Lee, et al.
Published: (1998-12-01)

Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes
by: Liping Hao, et al.
Published: (2021-07-01)

Dies Irae
by: Jean-Luc Nancy
Published: (2017-08-01)

Immune-related adverse events and the balancing act of immunotherapy
by: Michael Conroy, et al.
Published: (2022-01-01)

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> 2021, <i>13</i>, 6109
by: Dongyu Zhang, et al.
Published: (2022-09-01)

The IRA and the Partition of Ireland
by: Richard English
Published: (2023-12-01)

As vinhas da ira
by: Eva Paulino Bueno
Published: (2010-10-01)

THE FLUCTUATIONS IN THE IRAS DISTRIBUTION
by: R. B. Shatsova, et al.
Published: (2017-04-01)

Interview with Ira Gessel
by: ECA Interviews
Published: (2021-08-01)

Las iras de Aquiles
by: Francesco De Martino
Published: (2023-11-01)

La ira de Eneas
by: Karl Galinsky
Published: (2002-11-01)

Estado e religião no Irã
by: Rolf Reichert
Published: (1983-01-01)

Related-Key Differential Analysis of the AES
by: Christina Boura, et al.
Published: (2023-12-01)

UM PROJETO DE ESCRITA AUTORAL INTERMIDIÁTICA: O VÍDEO-ENSAIO DIES IRAE, HOMINES IRAE
by: Carolina Vanso França
Published: (2019-12-01)